H
Loading...
Loading...
CDC-scale OA burden is real (tens of millions of U.S. adults). Biologic OA care is symptom and function support — PRP or tissue options — not a disease-modifying FDA indication unless a specific product has one. Most do not.
Written for licensed providers. Reviewed by Joe Bradley, Founder & CEO. Content version 2026-09-18.
Biologic therapy options for osteoarthritis management. Help patients manage joint degeneration with regenerative treatments.
OA biologics fail when the diagnosis is “knee pain” and the note has no imaging or failed conservative care. PRP and viscosupplementation are different tickets. Pick one protocol per phenotype and staff it.
We will not tell you a 361 allograft reverses osteoarthritis. Counseling should match evidence and label.
Inflammatory flares, mechanical overload, and post-traumatic OA do not respond identically. Phenotype before SKU.
Medicare, Advantage, and cash-pay sports medicine will not share one script. Build two.
No.
Often historically; repeat steroids have cartilage concerns. Sequence is clinical.
Protocol-specific; document medical necessity for repeats.
Different access and guidance. Privileging separately is wise.
Contact us today to learn how Hawk Medical can support your practice.
We're not just a distributor - we're healthcare providers who understand your challenges
We own and operate medical clinics, so we understand your real-world challenges
All products meet strict regulatory requirements including HCT/P 361 compliance
Personal account management and ongoing training for your entire team
10+ years of experience helping practices implement successful programs
Learn more about related treatments, solutions, and resources
Experience the difference of working with a distributor who understands your practice because we operate one ourselves.